Stay updated with breaking news from Iontech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BioNTech’s alliance with DualityBio gives it two antibody drug conjugate (ADC) candidates, the most advanced of which is in mid-stage clinical development for solid tumors. It addresses the same target as a potential blockbuster AstraZeneca drug.
Consolidated Financial Statements BioNTech SE, Mainz as of December 31, 2022 Consolidated Statements of Profit or Loss Years ended ... | March 29, 2023
The company is expecting this drop in demand to accelerate through 2023.
MAINZ, Germany, March 28, 2023 -- BioNTech SE today announced that it has entered into a new share repurchase program , pursuant to which the Company may purchase American Depositary Shares,... | March 28, 2023
Anticipating demand, private clinics charging up to HK$2,800 per shot have advertised on social media since January.